Back to top

Analyst Blog

Positive news flowed in at Nymox Pharmaceutical Corporation recently when the Independent Data Monitoring Committee (IDMC) reported the third positive analysis of safety data from the company’s ongoing phase II study (NX03-0040) of NX-1207 for low grade localized prostate cancer.  

The IDMC’s interim safety analysis found no significant safety concerns associated with the use of NX-1207 for the treatment of low risk localized prostate cancer. The NX03-0040 study is assessing the efficacy and safety of both low (2.5 mg) and high (15 mg) single doses of NX-1207 in eradicating or shrinking low grade localized prostate cancer tumors. The phase II study is ongoing and is expected to be completed by May 2013.

NX-1207 is in phase III development both in the US and Europe for the treatment of patients suffering from benign prostatic hyperplasia (BPH). In Europe, the company has a licensing agreement with Recordati S.p.A. Recordati is sponsoring the recently initiated phase III study in Europe.

We note that the prostrate cancer market offers a lucrative opportunity. Currently approved prostate cancer treatments include Johnson & Johnson’s (JNJ - Analyst Report) Zytiga. Moreover, the prostate cancer market saw a new entrant in Aug 2012 in the form of Medivation’s (MDVN - Analyst Report) Xtandi (enzalutamide).

Nymox Pharma currently carries a Zacks Rank #3 (Hold). Stocks that currently look attractive in the pharma space include companies like Cytokinetics, Inc. (CYTK - Snapshot Report) carrying a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%